Pathstone Holdings’s GeneDx Holdings WGS Stock Holding History

Pathstone Holdings’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-57,439	Closed	-$158K	–	2356
2023 Q4	$158K	Buy	+57,439	New	+$134K	﹤0.01%	2093

Other funds holding WGS

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Pathstone Holdings's WGS Position: Q1 2024 in Review

Pathstone Holdings sold out of GeneDx Holdings (WGS) in Q1 2024, closing a stake of 57,439 shares — an estimated $158K sold.

Pathstone Holdings first reported a position in WGS in Q4 2023 and held it in 1 quarter. The position peaked at $158K in Q4 2023. 58 funds tracked by Wall St. Rank hold WGS as of Q1 2024.

Pathstone Holdings reported no remaining GeneDx Holdings position as of Q1 2024 after selling out during the quarter.
Pathstone Holdings sold 57,439 GeneDx Holdings shares in Q1 2024, an estimated $158K.
Pathstone Holdings first reported a position in GeneDx Holdings in Q4 2023 and held it in 1 quarter.
Pathstone Holdings's GeneDx Holdings position peaked at $158K in Q4 2023.
58 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2024.

Based on Pathstone Holdings's 13F filing for Q1 2024, filed 13 May 2024.